Graffinity enters discovery collaboration with Genentech

21 Oct 2009 | News

Collaboration

Fragment-based drug discovery specialist Graffinity Pharmaceuticals has agreed a drug discovery research collaboration with Genentech.

Under the terms of the agreement, Graffinity will receive technology access fees and optional payments for follow-up chemistry for the generation of novel, small-molecule hits against a number of drug targets. Financial details of the transaction were not disclosed. This is the second agreement between the two companies.

Never miss an update from Science|Business:   Newsletter sign-up